In preclinical ovarian cancer models, ASA treatment determined a significant reduction in Bcl-2 protein level with concomitant increase in caspase 3, revealing its antitumor and antiangiogenic effects (Huang et al., 2016). This evidence concerns the gene BCL2 and ovarian carcinoma.